LATEST EDUCATION NEWS
Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA® (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine
KEYTRUDA® (pembrolizumab), Merck's Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy...
Middle East Venture Partners (MEVP) Announces First Close of $30 Million Middle East Venture Fund II
Morehouse School of Medicine Receives $1.2 Million Grant from United Health Foundation and Optum to Help Build Healthier Communities in Atlanta